News
A new, easier-to-administer and patient-friendly sustained-release formulation of flucytosine, a medicine used to treat cryptococcal meningitis, has entered Phase II clinical trials in Malawi and ...
AllAfrica on MSN3d
New Treatment For Cryptococcal Meningitis Enters Phase II Trial As Global HIV Funding Cuts Threaten To Cause A Massive Increase In Advanced HIV DiseaseCryptococcal meningitis, the second-leading cause of HIV-related deaths, is expected to rise as access to care weakens and advanced HIV disease (previously called AIDS) increases.A new, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback